COMP <GO>
EBS vs MRK // RSI-14 & 200D SMA MOMENTUM
Emergent BioSolutions Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: EBS 4
— MRK 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: EBS
LAST: $6.81 (-5.68%) • MKT CAP: $370.2M
rsi-technicals
59.1
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
51.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.10% | 74.80% | -18.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 20.70% | -11.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 15.3x | -8.70 | EBS | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 13.50% | 34.30% | -20.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 28.10% | -21.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -28.80% | 1.30% | -30.10 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 5.19 | -3.78 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EBS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 59.1 | 51.7 | +7.40 | EBS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 18.4x | -11.90 | EBS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $370.2M | $361.02B | -$360.65B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | MRK REV | EBS GROSS % | MRK GROSS % | EBS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $65.01B | 56.1% | 74.8% | $156.8M | $12.36B |
| FY 2024 | $1.04B | $64.17B | 34.7% | 76.3% | $35.8M | $18.10B |
| FY 2023 | $1.05B | $60.12B | — | — | -$206.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
MRK // BETA 0.92